Emerging Computational Oncology Opportunities to Guide Precision Cancer Medicine
Inherited and environmental influences can put people at greater risk of cancer and impact their response/resistance to treatment. In this presentation, Dr. Eliezer Van Allen will describe how a patient’s cancer genome can be used to guide individualized treatment choices for precision medicine. He will examine how to identify treatment resistance mechanisms and show how certain phenotypic patterns can be paired with new modes of computation to further inform treatment decisions.
Dr. Eliezer Van Allen is an associate professor of medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an associate member at the Broad Institute of MIT and Harvard. His research focuses on computational cancer genomics, the application of new technologies (such as massively parallel sequencing to precision cancer medicine), and resistance to targeted therapeutics. As both a computational biologist and medical oncologist, Dr. Van Allen blends expertise in clinical computational oncology with analytic and programming skills to interpret genomic data for clinically focused questions.
- Using the Genomic Data Commons APIApril 26, 2021